Bromodomain inhibitors regulate the C9ORF72 locus in ALS

Experimental Neurology

Volumn 271, Issue , 2015, Pages 241-250

  Zeier, Zane ^a   Esanov, Rustam ^a   Belle, Kinsley C ^a   Volmar, Claude Henry ^a   Johnstone, Andrea L ^a   Halley, Paul ^a   DeRosa, Brooke A ^a   Khoury, Nathalie ^a   van Blitterswijk, Marka ^b   Rademakers, Rosa ^b   Albert, Jeffrey ^c   Brothers, Shaun P ^a   Wuu, Joanne ^a   Dykxhoorn, Derek M ^a   Benatar, Michael ^a   Wahlestedt, Claes ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c IntelliSyn RandD   (Canada)

Author keywords

Amyotrophic lateral sclerosis; BET; Bromodomain; C9ORF72; Repeat expansion

Indexed keywords

BROMODOMAIN INHIBITOR; MESSENGER RNA; SMALL INTERFERING RNA; ADENOSINE TRIPHOSPHATE; BENZODIAZEPINE DERIVATIVE; C9ORF72 PROTEIN, HUMAN; DEOXYCYTIDINE; ENZYME INHIBITOR; GSK525762A; PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; C9ORF72 GENE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FIBROBLAST; FMR1 GENE; FXN GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR PATHOLOGY; MOTONEURON; PRIORITY JOURNAL; PROTEIN TARGETING; UPREGULATION; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC TRANSFECTION; GENETICS; LYMPHOCYTE; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; TRANSFORMED CELL LINE;

ADENOSINE TRIPHOSPHATE; AMYOTROPHIC LATERAL SCLEROSIS; BENZODIAZEPINES; CELL CYCLE; CELL LINE, TRANSFORMED; DEOXYCYTIDINE; DNA METHYLATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE LIBRARY; HUMANS; LYMPHOCYTES; MUTATION; NEURONS; PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84934986151     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.06.017     Document Type: Article

References (73)

1. Almeida S., Gascon E., Tran H., et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013, 126(3):385-399. (Sep).
2. Anand P., Brown J.D., Lin C.Y., et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154(3):569-582.
3. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11(5):384-400. (May).
4. Ash P.E., Bieniek K.F., Gendron T.F., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77(4):639-646.
5. Bell M.V., Hirst M.C., Nakahori Y., et al. Physical mapping across the Fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 1991, 64(4):861-866.
6. Belzil V.V., Bauer P.O., Prudencio M., et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 2013, 126(6):895-905. (Dec).
7. Belzil V.V., Bauer P.O., Gendron T.F., Murray M.E., Dickson D., Petrucelli L. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res. 2014, 1584:15-21.
8. Biacsi R., Kumari D., Usdin K. SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet. 2008, 4(3):e1000017. (Mar).
9. Bostock C.J., Prescott D.M., Kirkpatrick J.B. An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. Exp. Cell Res. 1971, 68(1):163-168. (Sep).
10. Chiurazzi P., Pomponi M.G., Willemsen R., Oostra B.A., Neri G. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 1998, 7(1):109-113. (Jan).
11. Christman J.K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21(35):5483-5495.
12. Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013, 74(2):180-187. (Aug).
13. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478(7370):529-533.
14. Dawson M.A., Prinjha R.K., Dittman A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (London) 2011, 478:529-533. (Copyright (C) 2013 American Chemical Society (ACS). All Rights Reserved).
15. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72(2):245-256.
16. Delmore J.E., Issa G.C., Lemieux M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917.
17. Didonna A., Opal P. The promise and perils of HDAC inhibitors in neurodegeneration. Ann. Clin. Transl. Neurol. 2015, 2(1):79-101. (Jan).
18. Donnelly C.J., Zhang P.W., Pham J.T., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013, 80(2):415-428.
19. Ebert A.D., Shelley B.C., Hurley A.M., et al. EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res. 2013, 10(3):417-427. (May).
20. Evans-Galea M.V., Carrodus N., Rowley S.M., et al. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann. Neurol. 2012, 71(4):487-497. (Apr).
21. Filippakopoulos P., Qi J., Picaud S., et al. Selective inhibition of BET bromodomains. Nature 2010, 468(7327):1067-1073.
22. Filippakopoulos P., Picaud S., Fedorov O., et al. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg. Med. Chem. 2012, 20(6):1878-1886.
23. Floyd S.R., Pacold M.E., Huang Q., et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 2013, 498(7453):246-250.
24. Fratta P., Poulter M., Lashley T., et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 2013, 126(3):401-409. (Sep).
25. Gijselinck I., Van Langenhove T., van der Zee J., et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012, 11(1):54-65. (Jan).
26. He F., Todd P.K. Epigenetics in nucleotide repeat expansion disorders. Semin. Neurol. 2011, 31(5):470-483. (Nov).
27. Huang B., Yang X.D., Zhou M.M., Ozato K., Chen L.F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009, 29(5):1375-1387. (Mar).
28. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19(4):523-534.
29. Johnstone A.L., Reierson G.W., Smith R.P., Goldberg J.L., Lemmon V.P., Bixby J.L. A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates. Mol. Cell. Neurosci. 2012, 50(2):125-135. (Jun).
30. Kelly T.K., De Carvalho D.D., Jones P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010, 28(10):1069-1078.
31. Kumari D., Usdin K. Is Friedreich ataxia an epigenetic disorder?. Clin. Epigenet. 2012, 4(1):2.
32. Levine T.P., Daniels R.D., Gatta A.T., Wong L.H., Hayes M.J. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013, 29(4):499-503.
33. Li X.J., Du Z.W., Zarnowska E.D., et al. Specification of motoneurons from human embryonic stem cells. Nat. Biotechnol. 2005, 23(2):215-221. (Feb).
34. Liu W., Ma Q., Wong K., et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155(7):1581-1595.
35. Liu E.Y., Russ J., Wu K., et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol. 2014, 128(4):525-541. (Oct).
36. Loven J., Hoke H.A., Lin C.Y., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153(2):320-334.
37. Majounie E., Renton A.E., Mok K., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012, 11(4):323-330. (Apr).
38. Matzuk M.M., McKeown M.R., Filippakopoulos P., et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150(4):673-684.
39. Meyer-Franke A., Kaplan M.R., Pfrieger F.W., Barres B.A. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 1995, 15(4):805-819. (Oct).
40. Mirguet O., Gosmini R., Toum J., et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 2013, 56(19):7501-7515.
41. Mochizuki K., Nishiyama A., Jang M.K., et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J. Biol. Chem. 2008, 283(14):9040-9048.
42. Mori K., Weng S.M., Arzberger T., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339(6125):1335-1338.
43. Nicodeme E., Jeffrey K.L., Schaefer U., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468(7327):1119-1123.
44. Nuytemans K., Bademci G., Kohli M.M., et al. C9ORF72 Intermediate repeat copies are a significant risk factor for Parkinson disease. Ann. Hum. Genet. 2013, 77(5):351-363. (Sep).
45. Ott C.J., Kopp N., Bird L., et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120(14):2843-2852.
46. Patel M.C., Debrosse M., Smith M., et al. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell. Biol. 2013, 33(12):2497-2507. (Jun).
47. Pieretti M., Zhang F.P., Fu Y.H., et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66(4):817-822.
48. Pietrobono R., Pomponi M.G., Tabolacci E., Oostra B., Chiurazzi P., Neri G. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res. 2002, 30(14):3278-3285.
49. Prinjha R.K., Witherington J., Lee K. Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol. Sci. 2012, 33(3):146-153. (Mar).
50. Rahman S., Sowa M.E., Ottinger M., et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31(13):2641-2652. (Jul).
51. Rai M., Soragni E., Jenssen K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008, 3(4):e1958.
52. Rai M., Soragni E., Chou C.J., et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010, 5(1):e8825.
53. Renton A.E., Majounie E., Waite A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72(2):257-268.
54. Russ J., Liu E.Y., Wu K., et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. 2015, 129(1):39-52. (Jan).
55. Sandi C., Pinto R.M., Al-Mahdawi S., et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 2011, 42(3):496-505. (Jun).
56. Sandi C., Sandi M., Anjomani Virmouni S., Al-Mahdawi S., Pook M.A. Epigenetic-based therapies for Friedreich ataxia. Front. Genet. 2014, 5:165.
57. Shi J., Vakoc C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54(5):728-736.
58. Stoger R., Genereux D.P., Hagerman R.J., Hagerman P.J., Tassone F., Laird C.D. Testing the FMR1 promoter for mosaicism in DNA methylation among CpG sites, strands, and cells in FMR1-expressing males with fragile X syndrome. PLoS One 2011, 6(8):e23648.
59. Tassone F., Hagerman R.J., Taylor A.K., Hagerman P.J. A majority of Fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J. Med. Genet. 2001, 38(7):453-456. (Jul).
60. Todd P.K., Oh S.Y., Krans A., et al. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of Fragile X tremor ataxia syndrome. PLoS Genet. 2010, 6(12):e1001240.
61. Usdin K., House N.C., Freudenreich C.H. Repeat instability during DNA repair: insights from model systems. Crit. Rev. Biochem. Mol. Biol. 2015, 50(2):142-167. (Mar-Apr).
62. van Blitterswijk M., DeJesus-Hernandez M., Niemantsverdriet E., et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013, 12(10):978-988. (Oct).
63. Vincent A., Heitz D., Petit C., Kretz C., Oberle I., Mandel J.L. Abnormal pattern detected in Fragile-X patients by pulsed-field gel electrophoresis. Nature 1991, 349(6310):624-626.
64. Volmar C.H., Wahlestedt C. Histone deacetylases (HDACs) and brain function. Neuroepigenetics 2015, 1(1):20-27. (January).
65. Wu S.Y., Lee A.Y., Lai H.T., Zhang H., Chiang C.M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 2013, 49(5):843-857.
66. Xi Z., Zinman L., Moreno D., et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 2013, 92(6):981-989.
67. Xi Z., Rainero I., Rubino E., et al. Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum. Mol. Genet. 2014, 23(21):5630-5637.
68. Xi Z., Zhang M., Bruni A.C., et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 2015, 129(5):715-727. (May).
69. Yang Z., Yik J.H., Chen R., et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19(4):535-545.
70. Yang Z., He N., Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 2008, 28(3):967-976. (Feb).
71. Zhang D., Iyer L.M., He F., Aravind L. Discovery of Novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front. Genet. 2012, 3:283.
72. Zhang W., Prakash C., Sum C., et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 2012, 287(51):43137-43155.
73. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478(7370):524-528.